These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8738669)

  • 21. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
    First MR
    Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
    Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
    Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreas transplantation with ATG vs OKT3.
    Rosenberg L
    Transplant Proc; 1997 Nov; 29(7A):35S-36S. PubMed ID: 9366927
    [No Abstract]   [Full Text] [Related]  

  • 24. [Reduction of TNF-alpha release and clinical effects of the first injection of OKT3].
    Meulders Q; Dallel T; Peraldi MN; Kanfer A; Sraer JD; Rondeau E
    Presse Med; 1992 Dec; 21(41):2024-6. PubMed ID: 1294974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract]   [Full Text] [Related]  

  • 27. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
    Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
    J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection.
    Midtvedt K; Fauchald P; Lien B; Hartmann A; Albrechtsen D; Bjerkely BL; Leivestad T; Brekke IB
    Clin Transplant; 2003 Feb; 17(1):69-74. PubMed ID: 12588325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble interleukin-2 receptor (S IL-2R) in renal and pancreatic transplantation.
    Touraine F; Malcus C; Pouteil-Noble C; Touraine JL
    Eur Cytokine Netw; 1991; 2(1):47-50. PubMed ID: 1651783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of rabbit antithymocyte serum (RATS) and OKT3 on peripheral blood mononuclear cell subsets following renal transplantation.
    Zaltzman JS; Cole EH; Freedman J
    Clin Transplant; 1994 Dec; 8(6):516-22. PubMed ID: 7865912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Kidney-pancreas transplantation. Clinical results in 23 consecutive patients].
    Maestri M; Krieger N; Kuo P; Dafoe DC; Alfrey EJ
    Minerva Chir; 1998 Mar; 53(3):121-8. PubMed ID: 9617106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
    Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
    Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNF-alpha therapy for acute rejection in intestinal transplantation.
    Pascher A; Klupp J; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 Apr; 37(3):1635-6. PubMed ID: 15866693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies.
    Sabat R; Höflich C; Döcke WD; Oppert M; Kern F; Windrich B; Rosenberger C; Kaden J; Volk HD; Reinke P
    Intensive Care Med; 2001 Jun; 27(6):987-91. PubMed ID: 11497157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute pancreatitis complicating OKT3 administration for resistant cardiac rejection.
    Scheinin S; Radovancevic B; Frazier OH
    Transplant Proc; 1993 Jun; 25(3):2368-9. PubMed ID: 8516933
    [No Abstract]   [Full Text] [Related]  

  • 38. OKT3 in renal allografts: survival and complications.
    D'Souza RJ; Kwan JT; Chang R; Bending MR
    Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
    [No Abstract]   [Full Text] [Related]  

  • 39. [The clinical effect of ATG and OKT3 on the treatment of refractory rejection after cadavaric kidney transplantation].
    Ao J; Li Y; Xiao X; Yang W
    Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):542-4. PubMed ID: 11825460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with poly- and monoclonal antilymphocyte antibodies: assessment of efficacy and safety in transplantation.
    Claesson K; Tufveson G; Wahlberg J
    Transplant Proc; 1992 Feb; 24(1):314. PubMed ID: 1539293
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.